Home › Smoldering Multiple Myeloma › Michigan
Smoldering Multiple Myeloma clinical trials in Michigan
4 studies for Smoldering Multiple Myeloma are looking for participants at sites in Michigan.
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
- Barbara Ann Karmanos Cancer Institute - Detroit, Detroit
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07393282Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
- MyMichigan Medical Center Gratiot, Alma
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- University of Michigan Rogel Cancer Center, Ann Arbor
- and 42 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT03937635A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
- University of Michigan Health, Ann Arbor
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 8, 2026 · NCT06140524Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
- West Michigan Cancer Center, Kalamazoo
RecruitingObservational study
Ages 18 and older · All sexes · Updated May 7, 2026 · NCT02269592From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.